Untreated bladder cancer has a high mortality rate. In bladder cancer patients, urinary symptoms and sexual function are often assessed. Use of the SF-36 Questionnaire to assess disease-related quality of life (QoL). Current use in bladder cancer is restricted. The SF-36 was used to assess QoL in patients with bladder cancer at H. Adam Malik General Hospital Medan. This study was designed to assess the QoL bladder cancer patients undergoing these therapeutic protocols via the SF-36 questionnaire. The study included all patients with bladder cancer treated with TURBT, chemoradiotherapy, or radical cystectomy at H. Adam Malik General Hospital Medan's Department of Surgery. From January to December 2020, we recruited. The SF-36 questionnaire was used to assess QoL. A total of 36 patients were enrolled in this study with male predominance (66.67%) and the mean age was 55.64 ± 14.1 years. Muscle invasive was found to be the most diagnosed stage of bladder cancer (66.67%), and majority of the patients underwent TURBT (55.56%). All therapeutic protocols were mainly carried out in muscle invasive stage, while those undergoing the therapeutic protocols in H. Adam Malik General Hospital had a lower value (<50) than the normative value (50) which indicated a poor QoL. The QoL of bladder cancer patients undergoing TURBT, chemoradiotherapy and radical cystectomy were poor.